3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Melanoma
4
Skin Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Squamous Cell
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Kidney Neoplasms
1
Eyelid Squamous Cell Carcinoma
1
Cutaneous Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Merkel Cell
1
Carcinoma, Large Cell
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Anus Neoplasms
1
Adenocarcinoma
1
Interventions
Radiosurgery
23
Radiotherapy
20
Temozolomide
17
Lomustine
9
Bevacizumab
8
Surgical Procedures, Operative
7
Procarbazine
6
Vincristine
5
Nivolumab
5
Memantine
5
Magnetic Resonance Spectroscopy
4
Filgrastim
4
Etoposide
4
Cisplatin
4
Carboplatin
4
Specimen Handling
3
Sodium Chloride
3
Radiation
3
Methylphenidate
3
Mental Status and Dementia Tests
3
Granulocyte Colony-Stimulating Factor
3
Gefitinib
3
Cyclophosphamide
3
Corticotropin-Releasing Hormone
3
Carmustine
3
icotinib
2
etoposide phosphate
2
efaproxiral
2
X-Rays
2
Tranexamic Acid
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Brain Neoplasms
×
cemiplimab
×
Clear all
NCT05317858
2026-04-16
LIMITLESS
InSightec
Phase 3
Recruiting
30 enrolled